| Nov 19 |
Revance Therapeutics gains as Crown Labs further extends tender offer
|
| Nov 12 |
Revance Therapeutics jumps after Crown Laboratories tender offer extended again
|
| Nov 8 |
Revance Therapeutics sinks amid `going concern' disclosure
|
| Nov 7 |
Revance Therapeutics, Inc. (RVNC) Reports Q3 Loss, Lags Revenue Estimates
|
| Nov 7 |
Revance Therapeutics GAAP EPS of -$0.37 beats by $0.01, revenue of $59.88M misses by $8.3M
|
| Nov 7 |
Revance Reports Third Quarter 2024 Financial Results, Provides Corporate Update
|
| Oct 28 |
PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday
|
| Oct 28 |
Revance Therapeutics surges after Crown tender offer extended, settles with Teoxane
|
| Oct 25 |
Revance Therapeutics drops as deadline for Crown Lab tender set to expire
|
| Oct 4 |
Revance Therapeutics, Crown Labs tender offer extended until Oct. 18
|
